Efficacy and safety of once-daily inhaled umeclidinium in Asian patients with COPD: results from a randomized, placebo-controlled study
N Zhong, J Zheng, SH Lee, DA Lipson… - … Obstructive Pulmonary …, 2020 - Taylor & Francis
… This 24-week, Phase III, randomized, double-blind, parallel-group study (GSK study …
study, benefits in Asian patients with COPD have also been reported in studies of other LAMAs…
study, benefits in Asian patients with COPD have also been reported in studies of other LAMAs…
Dual therapy strategies for COPD: the scientific rationale for LAMA+ LABA
JS Cohen, MC Miles, JF Donohue… - … obstructive pulmonary …, 2016 - Taylor & Francis
… A dose ranging study of UMEC identified that once-daily dosing at 62.5 or 125 μg was …
being tested with LAMAs such as GLY and novel LAMAs. Previous studies of LAMA/LABAs using …
being tested with LAMAs such as GLY and novel LAMAs. Previous studies of LAMA/LABAs using …
Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies
TM Siler, E Kerwin, K Singletary, J Brooks… - … Obstructive Pulmonary …, 2016 - Taylor & Francis
… The LAMA umeclidinium (UMEC, GSK573719; GSK, London, UK) has recently been …
for COPD in the US and EU (Citation7,Citation8). Early dose-ranging studies demonstrated …
for COPD in the US and EU (Citation7,Citation8). Early dose-ranging studies demonstrated …
[HTML][HTML] Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease
L Condreay, L Huang, E Harris, J Brooks, JH Riley… - Respiratory …, 2016 - Elsevier
… muscarinic antagonists (LAMAs) for chronic obstructive pulmonary disease (COPD) is standard,
but … to umeclidinium (UMEC, a LAMA), vilanterol (VI, a LABA), and combination therapy. …
but … to umeclidinium (UMEC, a LAMA), vilanterol (VI, a LABA), and combination therapy. …
Inhaled umeclidinium in COPD patients: a review and meta-analysis
… patients. Umeclidinium provides a safe and effective option as an inhaled LAMA for the
management of COPD… To determine the optimal dose of the agent, dose-ranging studies in …
management of COPD… To determine the optimal dose of the agent, dose-ranging studies in …
[HTML][HTML] … of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients with COPD: Pooled Results of Randomized Placebo-Controlled Trials
TM Siler, E Kerwin, L Tombs, WA Fahy, I Naya - Pulmonary Therapy, 2016 - Springer
… number of randomized, double-blind clinical trials, … , GSK573719; GSK, London, UK) is a
once-daily LAMA indicated for the maintenance treatment of patients with symptomatic COPD [8…
once-daily LAMA indicated for the maintenance treatment of patients with symptomatic COPD [8…
A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD
G Feldman, F Maltais, S Khindri… - … of Chronic Obstructive …, 2016 - Taylor & Francis
… antagonists (LAMAs) are an integral part of management in stable COPD and have been …
) was the only LAMA available for patients with COPD. Citation6 Three other LAMAs, aclidinium …
) was the only LAMA available for patients with COPD. Citation6 Three other LAMAs, aclidinium …
Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
TE Albertson, WS Bowman, RW Harper… - … of Chronic Obstructive …, 2019 - Taylor & Francis
… triple (LAMA, LABA, ICS) therapy were randomized to remove the ICS. Citation9 This 26-week,
randomized, double-blind, triple-dummy study was of 1,053 COPD patients who were …
randomized, double-blind, triple-dummy study was of 1,053 COPD patients who were …
Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy
KS Babu, JB Morjaria - Therapeutic Advances in Chronic …, 2017 - journals.sagepub.com
… new LAMA currently approved for use in patients with COPD … COPD patients from two phase
III, randomized, double-blind, … Vil trifenatate is a novel selective LABA with bronchodilatory …
III, randomized, double-blind, … Vil trifenatate is a novel selective LABA with bronchodilatory …
A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
T Rheault, S Khindri, M Vahdati-Bolouri… - … Open Research, 2016 - Eur Respiratory Soc
… study, although both LAMAs are reported to improve lung function compared with placebo in
patients with moderate-to-very-severe COPD … both LAMAs (UMEC [16, 17], GLYCO [18, 20]). …
patients with moderate-to-very-severe COPD … both LAMAs (UMEC [16, 17], GLYCO [18, 20]). …